These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33918221)

  • 1. A Novel LRRK2 Variant p.G2294R in the WD40 Domain Identified in Familial Parkinson's Disease Affects LRRK2 Protein Levels.
    Ogata J; Hirao K; Nishioka K; Hayashida A; Li Y; Yoshino H; Shimizu S; Hattori N; Imai Y
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918221
    [No Abstract]   [Full Text] [Related]  

  • 2. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.
    Xiong Y; Neifert S; Karuppagounder SS; Stankowski JN; Lee BD; Grima JC; Chen G; Ko HS; Lee Y; Swing D; Tessarollo L; Dawson TM; Dawson VL
    eNeuro; 2017; 4(2):. PubMed ID: 28321439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.
    Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F
    Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical heterogeneity of LRRK2 p.I2012T mutation.
    Fan TS; Wu RM; Chen PL; Chen TF; Li HY; Lin YH; Chen CY; Chen ML; Tai CH; Lin HI; Lin CH
    Parkinsonism Relat Disord; 2016 Dec; 33():36-43. PubMed ID: 27628070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease.
    Senchuk MM; Van Raamsdonk JM; Moore DJ
    Neurobiol Dis; 2021 Apr; 151():105267. PubMed ID: 33450392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
    Lin CH; Lin HY; Fang JM; Chen CC
    Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics; applications in familial Parkinson's disease.
    Li Y; Cookson MR
    J Neurochem; 2019 Nov; 151(4):446-458. PubMed ID: 31022302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
    Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
    Elife; 2020 Feb; 9():. PubMed ID: 32057291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations.
    Takanashi M; Funayama M; Matsuura E; Yoshino H; Li Y; Tsuyama S; Takashima H; Nishioka K; Hattori N
    Acta Neuropathol Commun; 2018 Oct; 6(1):105. PubMed ID: 30333048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
    Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
    Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and Environmental Factors Influence the Pleomorphy of
    Chittoor-Vinod VG; Nichols RJ; Schüle B
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of LRRK2 in Neurodegeneration of Parkinson Disease.
    Rui Q; Ni H; Li D; Gao R; Chen G
    Curr Neuropharmacol; 2018; 16(9):1348-1357. PubMed ID: 29473513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the LRRK2 gene in Parkinsonism.
    Li JQ; Tan L; Yu JT
    Mol Neurodegener; 2014 Nov; 9():47. PubMed ID: 25391693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.
    Islam MS; Moore DJ
    Biochem Soc Trans; 2017 Feb; 45(1):163-172. PubMed ID: 28202670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics of Parkinson's disease: a review of SNCA and LRRK2.
    Konno T; Siuda J; Wszolek ZK
    Wiad Lek; 2016; 69(3 Pt 1):328-32. PubMed ID: 27486710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.